Satellos Bioscience Inc. develops clinical-stage biotechnology programs for degenerative muscle diseases, led by SAT-3247, an orally administered small molecule therapy designed to restore natural muscle repair and regeneration. Company news centers on Duchenne muscular dystrophy clinical development, including Phase 2 BASECAMP pediatric and TRAILHEAD adult studies, AAK1 biology, muscle-force and biomarker data, and research publications supporting its stem-cell-based approach.
Updates also cover regulatory clearances, scientific and investor conference presentations, board and leadership appointments, public financing activity, share consolidation, and exchange-listing developments tied to the company's common shares.
Satellos (TSX: MSCL, OTCQB: MSCLF; ticker MSLE) announced dosing of the first participant in BASECAMP, a three-month, randomized, double-blind, placebo-controlled Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy.
The proof-of-concept trial will enroll 51 ambulatory children aged 7–9, with primary endpoints of safety, tolerability and muscle force; secondary endpoints include muscle quality, function and regeneration. Satellos plans 25 sites across the United States, Europe, U.K., Australia, Canada and Serbia; the study is actively enrolling.
Satellos (TSX: MSCL; OTCQB: MSCLF) filed a preliminary prospectus supplement for a proposed public offering of common shares (or pre-funded warrants) and applied to list common shares on the Nasdaq Global Market under MSLE.
The company intends to use net proceeds to fund R&D, working capital and advancing SAT-3247 through Phase 2 to Phase 3 trials. The underwriters have a 30-day option for up to an additional 15% of the offering. The Registration Statement on Form F-10 became effective upon filing.
Satellos (GBIO) appointed Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs on January 29, 2026.
Ms. Paone joins from Generation Bio where she served as Chief Operating Officer and previously led regulatory strategy at Vertex, including work on Kalydeco and Orkambi. Satellos says her hire supports advancement of two SAT-3247 clinical studies in adult and pediatric DMD populations.
Satellos (TSX: MSCL, OTCQB: MSCLF) completed a 1-for-12 share consolidation to support a prospective Nasdaq listing. The consolidation reduces outstanding common shares from 185,507,153 to approximately 15,458,929 and takes effect on or about Jan 30, 2026 on the TSX.
The company applied to list on Nasdaq under MSLE, aims to meet Nasdaq's US$3.00 per-share requirement, updated its CUSIP (80401L803) and ISIN (CA80401L8033), and will round down fractional shares with no cash paid.
Satellos (OTCQB: MSCLF) received U.S. FDA IND clearance and authorizations from MHRA, TGA/HREC and ALIMS to start BASECAMP, a three-month, randomized, double-blind, placebo-controlled Phase 2 study of oral SAT-3247 in 51 ambulatory children with Duchenne. Primary endpoints are safety, tolerability and muscle force; secondary endpoints include muscle quality, function and regeneration. A Phase 1a/b adult study reported SAT-3247 was safe with PK support and showed mean grip-strength improvements of 118.6% (dominant) and 97.9% (non-dominant). First pediatric enrollment expected by end of 2025; interim BASECAMP data expected in Q2 2026.
Satellos Bioscience (OTCQB: MSCLF, TSX: MSCL) will participate in two investor conferences in New York in December 2025: Piper Sandler 37th Annual Healthcare Conference on Dec 3, 2025 at 12:50 p.m. ET (presentation, live webcast with replay) and Oppenheimer Movers in Rare Disease Summit on Dec 11, 2025 at 1:10 p.m. ET (panel on polypharmacy in DMD and neuromuscular disease).
The Satellos leadership team will also hold one-on-one investor meetings during the events; meeting requests can be made through Piper Sandler/Oppenheimer representatives or by emailing ir@satellos.com.
Satellos (OTCQB: MSCLF) announced a Nature Communications publication (Nov 18, 2025) reporting that Duchenne muscular dystrophy begins during fetal development as a muscle stem cell disease with loss of polarity and reduced myogenic progenitors.
Researchers showed that blocking the protein AAK1 restored stem cell polarity, progenitor production, and normal muscle formation in dystrophic models, supporting AAK1 inhibition and Satellos' candidate SAT-3247 as a regenerative approach.
Satellos (TSX: MSCL, OTCQB: MSCLF) reported Q3 2025 results and corporate updates on November 14, 2025. Key developments include the appointment of Mark Nawacki to the board, completion of an IND submission to the U.S. FDA and parallel global regulatory filings to support a Phase 2 pediatric trial of SAT-3247, and dosing the first patient in the long-term adult follow-up study LT-001.
Clinical data presented showed mean improvements in grip strength (dominant hand +118.6%, non-dominant +97.9%) and respiratory function (predicted FVC +5.8%) in Phase 1b participants. Financially, cash and short-term investments were $34.6M USD ($48.2M total) at Sept 30, 2025; Q3 net loss was $5.8M ($0.03/share). The company expects to enroll the first pediatric Phase 2 patient by end of 2025 and to report additional adult data in Q1 2026.
Satellos (OTCQB: MSCLF) announced that its leadership will participate in two investor conferences in November 2025: a fireside chat and 1x1 meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference on Nov 10, 2025 at 3:00 PM ET in Boston, and a presentation plus 1x1 meetings at the Stifel Healthcare Conference on Nov 12, 2025 at 2:40 PM ET in New York.
The fireside chat and presentation will be available via live webcast on the company’s Events and Presentations page, with a replay available after the presentations.
Satellos (OTCQB: MSCLF) announced the first adult patient has been dosed in LT-001, an open-label long-term follow-up study of SAT-3247 in adult males with Duchenne muscular dystrophy.
The 11-month study will evaluate safety, MRI muscle composition, functional outcomes, and serum biomarkers in participants who completed Part D of the Phase 1b study. Results after the initial 3 months are anticipated in early 2026, then reported quarterly. The trial is underway at St Vincent’s Hospital, Melbourne, with plans to enroll up to 10 new participants in Australia and to open sites in the U.S., subject to regulatory and site approvals.